Catalent Pharma Solutions has announced the multi-site expansion of its analytical and process development capabilities for biologics
“Our capabilities will allow us to seamlessly support our clients as they move through clinical development toward commercial production” - Riley
The company is a provider of standalone analytical services for large molecule products with knowledge in new biologics entities (NBEs), biosimilars, and antibody drug conjugates according to Catalent.
Catalent’s expansions include a development of bioassay and protein characterisation capabilities at it’s Kansas City, Missouri facility and integrated analytical capabilities at its Madison, Wisconsin bio-manufacturing facility.
The Kansas City investment enables the facility to offer dual and complementary options for kinetic and quantitative binding assays for characterisation and GMP testing.
The Madison facility provides development, manufacturing and analytical services for NBEs and biosimilars and the investment enables it to increase its large molecule characterisation capabilities.
Catalent will also expand process development capability at the Madison site, including integration of the Ambr 15 microbioreactor system into its cell line and upstream development process.
Brian Riley, Catalent’s general manager at Madison, said: “Integrating a broad range of analytical services with our GPEx cell line creation and manufacturing capabilities will allow us to seamlessly support our clients as they move through clinical development toward commercial production.”